Jan 18 |
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice
|
Dec 6 |
Optinose falls as FDA delays label expansion for Xhance product
|
Dec 6 |
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE
|
Nov 17 |
Owning 47% shares,institutional owners seem interested in OptiNose, Inc. (NASDAQ:OPTN),
|
Nov 9 |
OptiNose Inc (OPTN) Reports Q3 2023 Financial Results with Improved Operating Efficiency
|
Nov 9 |
OptiNose GAAP EPS of -$0.08, revenue of $19.8M
|
Nov 9 |
Optinose Reports Third Quarter 2023 Financial Results and Operational Updates
|